1. Home
  2. SEER vs ALDX Comparison

SEER vs ALDX Comparison

Compare SEER & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Seer Inc.

SEER

Seer Inc.

HOLD

Current Price

$1.98

Market Cap

97.3M

Sector

Health Care

ML Signal

HOLD

Logo Aldeyra Therapeutics Inc.

ALDX

Aldeyra Therapeutics Inc.

HOLD

Current Price

$1.66

Market Cap

101.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SEER
ALDX
Founded
2017
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
97.3M
101.1M
IPO Year
2020
2014

Fundamental Metrics

Financial Performance
Metric
SEER
ALDX
Price
$1.98
$1.66
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$5.50
AVG Volume (30 Days)
347.8K
2.3M
Earning Date
05-12-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
9.40
40.43
EPS
N/A
N/A
Revenue
$16,578,000.00
N/A
Revenue This Year
$2.14
N/A
Revenue Next Year
$25.90
N/A
P/E Ratio
N/A
N/A
Revenue Growth
16.99
N/A
52 Week Low
$1.65
$1.07
52 Week High
$2.41
$6.18

Technical Indicators

Market Signals
Indicator
SEER
ALDX
Relative Strength Index (RSI) 63.86 32.59
Support Level $1.87 $1.48
Resistance Level $2.13 $1.89
Average True Range (ATR) 0.06 0.11
MACD 0.03 0.12
Stochastic Oscillator 80.52 43.90

Price Performance

Historical Comparison
SEER
ALDX

About SEER Seer Inc.

Seer Inc is a life sciences company, develops and commercializes products to decode the biology of the proteome. The company offers Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. It markets and sells its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. The company operates in China, Australia, Eastern Europe, Israel, Japan and South Africa.

About ALDX Aldeyra Therapeutics Inc.

Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.

Share on Social Networks: